This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2022.
Program Description
Waldenström macroglobulinemia (WM) is a rare, incurable hematologic malignancy. Patient presentation is variable, ranging from asymptomatic to symptoms including hyperviscosity, neuropathy, and fever. Traditionally, WM has been treated with systemic chemotherapy; however, the use of oral Bruton's tyrosine kinase inhibitors, proteasome inhibitors, and monoclonal antibodies are now incorporated into clinical practice guidelines. This activity will focus on available drug therapies for the treatment of WM as well as clinical data supporting use of the agents. Additionally, the role of the pharmacist in assisting in patient care will be emphasized. Expert clinical faculty will guide learners through several patient case scenarios, allowing the opportunity for audience engagement in optimal therapy selection and adverse effect management.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 29, 2022
Expiration date: April 29, 2023
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the pathophysiology underlying Waldenström macroglobulinemia (WM), the clinical presentation, and associated complications
- Illustrate the current and emerging paradigm for the management of WM
- Identify the role of the pharmacist in implementing supportive care strategies to optimize outcomes for patients with WM
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
